Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices
CONCLUSION: This survey underscores the diverse and inadequate institutional policies on RhIG immunoprophylaxis after RhD exposure in Rh-negative patients via transfusion. This observation identifies an opportunity to improve transfusion safety.PMID:38534065 | DOI:10.1111/trf.17812 (Source: Transfusion)
Source: Transfusion - March 27, 2024 Category: Hematology Authors: Wen Lu Laura Stephens Aaron Shmookler Kerry O'Brien Julie Katz Karp Daniela Hermelin Sara Bakhtary Nour Almozain Melissa George Mark Fung Source Type: research
Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices
CONCLUSION: This survey underscores the diverse and inadequate institutional policies on RhIG immunoprophylaxis after RhD exposure in Rh-negative patients via transfusion. This observation identifies an opportunity to improve transfusion safety.PMID:38534065 | DOI:10.1111/trf.17812 (Source: Transfusion)
Source: Transfusion - March 27, 2024 Category: Hematology Authors: Wen Lu Laura Stephens Aaron Shmookler Kerry O'Brien Julie Katz Karp Daniela Hermelin Sara Bakhtary Nour Almozain Melissa George Mark Fung Source Type: research
Immune-globulin
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-globulin/Prednisone
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-globulin
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-globulin/Prednisone
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-globulin/insulin/mycophenolate-mofetil
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Antibacterials/immune-globulin
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-globulin/insulin/mycophenolate-mofetil
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Antibacterials/immune-globulin
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Society for Maternal-Fetal Medicine Statement: RhD immune globulin after spontaneous or induced abortion less than 12 weeks of gestation
Guidelines for management of first-trimester spontaneous and induced abortion vary regarding RhD testing and Rho(D) immune globulin administration. These existing guidelines are based on limited data that do not convincingly demonstrate the safety of withholding Rho(D) immune globulin for first-trimester abortions or pregnancy losses. Given the adverse fetal and neonatal outcomes associated with RhD alloimmunization, prevention of maternal sensitization is essential in RhD negative patients who may experience subsequent pregnancies. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - February 26, 2024 Category: OBGYN Authors: Society for Maternal-Fetal Medicine (SMFM), Malavika Prabhu, Judette M. Louis, Jeffrey A. Kuller, SMFM Publications Committee Tags: SMFM Statement Source Type: research
Guide to Rho(D) Immune Globulin in Women With Molecularly Defined Asian-type DEL (c.1227G & gt;A)
We report that mothers with molecularly defined Asian-type DEL, similar to those with weak D types 1, 2, 3, 4.0, and 4.1, do not require RhIG before and after delivery. Collectively, this review could pave the way for the revision of international guidelines to include the selective use of RhIG based on specific genotypes, particularly in women with the Asian-type DEL.PMID:38384203 | DOI:10.3343/alm.2023.0356 (Source: Annals of Laboratory Medicine)
Source: Annals of Laboratory Medicine - February 22, 2024 Category: Laboratory Medicine Authors: In Hwa Jeong SooHo Yu Tae Yeul Kim Soo-Young Oh Duck Cho Source Type: research
